Promising RNA-based cancer gene therapy using extracellular vesicles for drug delivery

References

• Elverum K, Whitman M. Delivering cellular and gene therapies to patients: solutions for realizing the potential of the next generation of medicine. Gene Ther. 2019. DOI:10.1038/s41434-019-0074-7
   PubMed Web of Science ®Google Scholar
• Sahin U, Derhovanessian E, Miller M, et al., Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222–226.
   PubMed Web of Science ®Google Scholar
• Verbeke R, Lentacker I, Wayteck L, et al. Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: restoring the immunogenicity of immunosilent mRNA. J Control Release. 2017;266:287–300.
   PubMed Web of Science ®Google Scholar
• Liu Y, Xu J, Choi HH, et al. Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer. Nat Commun. 2018;9(1):4718.
   PubMed Web of Science ®Google Scholar
• Wang Y, Su HH, Yang Y, et al. Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Ther. 2013;21(2):358–367.
   PubMed Web of Science ®Google Scholar
• Zhang R, Men K, Zhang X, et al. Delivery of a modified mRNA encoding IL-22 binding protein (IL-22BP) for colon cancer gene therapy. J Biomed Nanotechnol. 2018;14(7):1239–1251.
   PubMed Web of Science ®Google Scholar
• Lara H, Wang Y, Beltran AS, et al. Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors. J Biol Chem. 2012;287(35):29873–29886.
   PubMed Web of Science ®Google Scholar
• Limoni SK, Moghadam MF, Moazzeni SM, et al. Engineered exosomes for targeted transfer of siRNA to HER2 positive breast cancer cells. Appl Biochem Biotechnol. 2019;187(1):352–364.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang Y, Bai M, et al. Exosomes serve as nanoparticles to suppress tumor growth and angiogenesis in gastric cancer by delivering hepatocyte growth factor siRNA. Cancer Sci. 2018;109(3):629–641.
   PubMed Web of Science ®Google Scholar
• Pomatto MAC, Bussolati B, D’Antico S, et al. improved loading of plasma-derived extracellular vesicles to encapsulate antitumor miRNAs. Mol Ther Methods Clin Dev. 2019;13:133–144.
   PubMed Web of Science ®Google Scholar
• O’Brien KP, Khan S, Gilligan KE, et al. Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379. Oncogene. 2018;37(16):2137–2149.
   PubMed Web of Science ®Google Scholar
• Wang XY, Zhang HY, Bai M, et al. exosomes serve as nanoparticles to deliver anti-miR-214 to reverse chemoresistance to Cisplatin in gastric cancer. Mol Ther. 2018;26(3):774–783.
   PubMed Web of Science ®Google Scholar
• Usman WM, Pham TC, Kwok YY, et al., Efficient RNA drug delivery using red blood cell extracellular vesicles. Nat Commun. 2018;9(1):2359.
   PubMed Web of Science ®Google Scholar
• Tsui NB, Ng EK, Lo YM. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem. 2002;48(10):1647–1653.
   PubMed Web of Science ®Google Scholar
• Tong S, Moyo B, Lee CM, et al. Engineered materials for in vivo delivery of genome-editing machinery. Nat Rev Mater. 2019;4(11):726–737.
   PubMed Web of Science ®Google Scholar
• Islam MA, Xu Y, Tao W, et al. Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nat Biomed Eng. 2018;2(11):850–864.
   PubMed Web of Science ®Google Scholar
• Shu D, Li H, Shu Y, et al. Systemic delivery of anti-miRNA for suppression of triple negative breast cancer utilizing RNA nanotechnology. Acs Nano. 2015;9(10):9731–9740.
   PubMed Web of Science ®Google Scholar
• Lau S, Graham B, Cao N, et al. Enhanced extravasation, stability and in vivo cardiac gene silencing via in situ siRNA-albumin conjugation. Mol Pharm. 2012;9(1):71–80.
   PubMedGoogle Scholar
• Gao S, Dagnaes-Hansen F, Nielsen EJ, et al. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther. 2009;17(7):1225–1233.
   PubMed Web of Science ®Google Scholar
• Tang XR, Wen X, He QM, et al. MicroRNA-101 inhibits invasion and angiogenesis through targeting ITGA3 and its systemic delivery inhibits lung metastasis in nasopharyngeal carcinoma. Cell Death Dis. 2017;8(1):e2566.
   Web of Science ®Google Scholar
• Zheng F, Liao YJ, Cai MY, et al. Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targets. PLoS Genet. 2015;11(2):e1004873.
   PubMed Web of Science ®Google Scholar
• Borel F, Kay MA, Mueller C. Recombinant AAV as a platform for translating the therapeutic potential of RNA interference. Mol Ther. 2014;22(4):692–701.
   PubMed Web of Science ®Google Scholar
• Guan S, Rosenecker J. Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Ther. 2017;24(3):133–143.
   PubMed Web of Science ®Google Scholar
• Hydbring P, Wang Y, Fassl A, et al. Cell-cycle-targeting microRNAs as therapeutic tools against refractory cancers. Cancer Cell. 2017;31(4):576–90.e8.
   PubMed Web of Science ®Google Scholar
• Wilson R, Espinosa-Diez C, Kanner N, et al. MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment. Nat Commun. 2016;7:13597.
   PubMed Web of Science ®Google Scholar
• Oliveira AC, Raemdonck K, Martens T, et al. Stealth monoolein-based nanocarriers for delivery of siRNA to cancer cells. Acta Biomater. 2015;25:216–229.
   PubMed Web of Science ®Google Scholar
• Pramanik D, Campbell NR, Karikari C, et al. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther. 2011;10(8):1470–1480.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Shapiro GI, LoRusso PM, et al., First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013;3(4):406–417.
   PubMed Web of Science ®Google Scholar
• Xu X, Wu J, Liu Y, et al. Multifunctional envelope-type siRNA delivery nanoparticle platform for prostate cancer therapy. ACS Nano. 2017;11(3):2618–2627.
   PubMed Web of Science ®Google Scholar
• Cheng CJ, Bahal R, Babar IA, et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature. 2015;518(7537):107–110.
   PubMed Web of Science ®Google Scholar
• Varshney A, Panda JJ, Singh AK, et al. Targeted delivery of microRNA-199a-3p using self-assembled dipeptide nanoparticles efficiently reduces hepatocellular carcinoma in mice. Hepatology. 2018;67(4):1392–1407.
   PubMed Web of Science ®Google Scholar
• Uchida S, Kinoh H, Ishii T, et al. Systemic delivery of messenger RNA for the treatment of pancreatic cancer using polyplex nanomicelles with a cholesterol moiety. Biomaterials. 2016;82:221–228.
   PubMed Web of Science ®Google Scholar
• Wen D, Peng Y, Lin F, et al. Micellar delivery of miR-34a modulator rubone and paclitaxel in resistant prostate cancer. Cancer Res. 2017;77(12):3244–3254.
   PubMed Web of Science ®Google Scholar
• Binzel DW, Shu Y, Li H, et al. Specific delivery of miRNA for high efficient inhibition of prostate cancer by RNA nanotechnology. Mol Ther. 2016;24(7):1267–1277.
   PubMed Web of Science ®Google Scholar
• Yin HR, Wang HZ, Li ZF, et al. RNA micelles for the systemic delivery of anti-miRNA for cancer targeting and inhibition without ligand. Acs Nano. 2019;13(1):706–717.
   PubMed Web of Science ®Google Scholar
• Huang YH, Peng W, Furuuchi N, et al. Delivery of therapeutics targeting the mRNA-binding protein HuR using 3DNA nanocarriers suppresses ovarian tumor growth. Cancer Res. 2016;76(6):1549–1559.
   PubMed Web of Science ®Google Scholar
• Chen WQ, Liu Y, Liang X, et al. Chondroitin sulfate-functionalized polyamidoamine as a tumor-targeted carrier for miR-34a delivery. Acta Biomater. 2017;57:238–250.
   PubMed Web of Science ®Google Scholar
• Kim MW, Jeong HY, Kang SJ, et al. Anti-EGF receptor aptamer-guided co-delivery of anti-cancer siRNAs and quantum dots for theranostics of triple-negative breast cancer. Theranostics. 2019;9(3):837–852.
   PubMed Web of Science ®Google Scholar
• Yan W, Tao M, Jiang B, et al. Overcoming drug resistance in colon cancer by aptamer-mediated targeted co-delivery of drug and siRNA using grapefruit-derived nanovectors. Cell Physiol Biochem. 2018;50(1):79–91.
   PubMedGoogle Scholar
• Lei Y, Tang L, Xie Y, et al. Gold nanoclusters-assisted delivery of NGF siRNA for effective treatment of pancreatic cancer. Nat Commun. 2017;8:15130.
   PubMed Web of Science ®Google Scholar
• Chan C, Guo N, Duan X, et al. Systemic miRNA delivery by nontoxic nanoscale coordination polymers limits epithelial-to-mesenchymal transition and suppresses liver metastases of colorectal cancer. Biomaterials. 2019;210:94–104.
   PubMed Web of Science ®Google Scholar
• Sayed E, Haj-Ahmad R, Ruparelia K, et al. Porous inorganic drug delivery systems-a review. AAPS PharmSciTech. 2017;18(5):1507–1525.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xie Y, Kilchrist KV, et al. Endosomolytic and tumor-penetrating mesoporous silica nanoparticles for siRNA/miRNA combination cancer therapy. ACS Appl Mater Interfaces. 2020;12(4):4308-4322.
   Web of Science ®Google Scholar
• Lio DCS, Liu C, Oo MMS, et al. Transdermal delivery of small interfering RNAs with topically applied mesoporous silica nanoparticles for facile skin cancer treatment. Nanoscale. 2019;11(36):17041–17051.
   PubMed Web of Science ®Google Scholar
• Du X, Zhao C, Zhou M, et al. Hollow carbon nanospheres with tunable hierarchical pores for drug, gene, and photothermal synergistic treatment. Small. 2017;13:6.
   Web of Science ®Google Scholar
• Zhu S, Zhang J, Zhang L, et al. Inhibition of Kupffer cell autophagy abrogates nanoparticle-induced liver injury. Adv Healthc Mater. 2017;6:9.
   Web of Science ®Google Scholar
• Zhang J, Qin X, Wang B, et al. Zinc oxide nanoparticles harness autophagy to induce cell death in lung epithelial cells. Cell Death Dis. 2017;8(7):e2954.
   PubMedGoogle Scholar
• Kim B, Pang HB, Kang J, et al. Immunogene therapy with fusogenic nanoparticles modulates macrophage response to Staphylococcus aureus. Nat Commun. 2018;9(1):1969.
   PubMedGoogle Scholar
• Andaloussi SE, Mager I, Breakefield XO, et al. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013;12(5):347–357.
   PubMed Web of Science ®Google Scholar
• Pullan JE, Confeld MI, Osborn JK, et al. Exosomes as drug carriers for cancer therapy. Mol Pharm. 2019;16(5):1789–1798.
   PubMed Web of Science ®Google Scholar
• Tarasov VV, Svistunov AA, Chubarev VN, et al. Extracellular vesicles in cancer nanomedicine. Semin Cancer Biol. 2019. DOI:10.1016/j.semcancer.2019.08.017
   Web of Science ®Google Scholar
• Tominaga N, Kosaka N, Ono M, et al. Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat Commun. 2015;6:6716.
   Web of Science ®Google Scholar
• Alvarez-Erviti L, Seow Y, Yin H, et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29(4):341–345.
   PubMed Web of Science ®Google Scholar
• Munoz JL, Bliss SA, Greco SJ, et al. Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol Ther Nucleic Acids. 2013;2:e126.
   PubMedGoogle Scholar
• Yang T, Fogarty B, LaForge B, et al. Delivery of small interfering RNA to inhibit vascular endothelial growth factor in zebrafish using natural brain endothelia cell-secreted exosome nanovesicles for the treatment of brain cancer. Aaps J. 2017;19(2):475–486.
   PubMed Web of Science ®Google Scholar
• Morse MA, Garst J, Osada T, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med. 2005;3(1):9.
   PubMed Web of Science ®Google Scholar
• Merchant ML, Rood IM, Deegens JKJ, et al. Isolation and characterization of urinary extracellular vesicles: implications for biomarker discovery. Nat Rev Nephrol. 2017;13(12):731–749.
   PubMed Web of Science ®Google Scholar
• Lahibaks NF, Lei Z, Mol EA, et al. Biofabrication of cell-derived nanovesicles: a potential alternative to extracellular vesicles for regenerative medicine. Cells. 2019;8:12.
   Web of Science ®Google Scholar
• Zhao Z, McGill J, Gamero-Kubota P, et al. Microfluidic on-demand engineering of exosomes towards cancer immunotherapy. Lab Chip. 2019;19(10):1877–1886.
   PubMed Web of Science ®Google Scholar
• Milone MC, O’Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018;32(7):1529–1541.
   PubMed Web of Science ®Google Scholar
• Aghebati-Maleki A, Dolati S, Ahmadi M, et al. Nanoparticles and cancer therapy: perspectives for application of nanoparticles in the treatment of cancers. J Cell Physiol. 2020;235:1962-1972.
   Web of Science ®Google Scholar
• Senapati S, Mahanta AK, Kumar S, et al. Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther. 2018;3(1):7.
   PubMed Web of Science ®Google Scholar
• Liu J, Bu W, Pan L, et al. NIR-triggered anticancer drug delivery by upconverting nanoparticles with integrated azobenzene-modified mesoporous silica. Angewandte Chemie. 2013;52(16):4375–4379.
   Google Scholar
• Ha D, Yang N, Nadithe V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm Sin B. 2016;6(4):287–296.
   PubMed Web of Science ®Google Scholar
• Johnsen KB, Gudbergsson JM, Duroux M, et al. On the use of liposome controls in studies investigating the clinical potential of extracellular vesicle-based drug delivery systems - A commentary. J Control Release. 2018;269:10–14.
   PubMed Web of Science ®Google Scholar
• Van den Bergh JMJ, Smits E, Berneman ZN, et al. Monocyte-derived dendritic cells with silenced PD-1 ligands and transpresenting interleukin-15 stimulate strong tumor-reactive T-cell expansion. Cancer Immunol Res. 2017;5(8):710–715.
   PubMed Web of Science ®Google Scholar
• Zarghampoor F, Azarpira N, Khatami SR, et al. Improved translation efficiency of therapeutic mRNA. Gene. 2019;707:231–238.
   PubMed Web of Science ®Google Scholar
• Mizrak A, Bolukbasi MF, Ozdener GB, et al. Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth. Mol Ther. 2013;21(1):101–108.
   PubMed Web of Science ®Google Scholar
• Erkan EP, Senfter D, Madlener S, et al. Extracellular vesicle-mediated suicide mRNA/protein delivery inhibits glioblastoma tumor growth in vivo. Cancer Gene Ther. 2017;24(1):38–44.
   PubMed Web of Science ®Google Scholar
• Altanerova U, Benejova K, Altanerova V, et al. Dental pulp mesenchymal stem/stromal cells labeled with iron sucrose release exosomes and cells applied intra-nasally migrate to intracerebral glioblastoma. Neoplasma. 2016;63(6):925–933.
   PubMed Web of Science ®Google Scholar
• Altanerova U, Jakubechova J, Benejova K, et al. Prodrug suicide gene therapy for cancer targeted intracellular by mesenchymal stem cell exosomes. Int J Cancer. 2019;144(4):897–908.
   PubMed Web of Science ®Google Scholar
• Matuskova M, Hlubinova K, Pastorakova A, et al. HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells. Cancer Lett. 2010;290(1):58–67.
   PubMed Web of Science ®Google Scholar
• Hung ME, Leonard JN. A platform for actively loading cargo RNA to elucidate limiting steps in EV-mediated delivery. J Extracell Vesicles. 2016;5:31027.
   PubMed Web of Science ®Google Scholar
• Pastor F, Berraondo P, Etxeberria I, et al. An RNA toolbox for cancer immunotherapy. Nat Rev Drug Discov. 2018;17(10):751–767.
   PubMed Web of Science ®Google Scholar
• Conde J, Oliva N, Atilano M, et al. Self-assembled RNA-triple-helix hydrogel scaffold for microRNA modulation in the tumour microenvironment. Nat Mater. 2016;15(3):353–363.
   PubMed Web of Science ®Google Scholar
• Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods. 2007;4(9):721–726.
   PubMed Web of Science ®Google Scholar
• Murakami K, Miyagishi M. Tiny masking locked nucleic acids effectively bind to mRNA and inhibit binding of microRNAs in relation to thermodynamic stability. Biomed Rep. 2014;2(4):509–512.
   PubMedGoogle Scholar
• Zhang Y, Li L, Yu J, et al. Microvesicle-mediated delivery of transforming growth factor beta1 siRNA for the suppression of tumor growth in mice. Biomaterials. 2014;35(14):4390–4400.
   PubMed Web of Science ®Google Scholar
• Greco KA, Franzen CA, Foreman KE, et al. PLK-1 silencing in bladder cancer by siRNA delivered with exosomes. Urology. 2016;91(241):e17.
   Google Scholar
• Yang Z, Xie J, Zhu J, et al. Functional exosome-mimic for delivery of siRNA to cancer: in vitro and in vivo evaluation. J Control Release. 2016;243:160–171.
   PubMed Web of Science ®Google Scholar
• Lunavat TR, Jang SC, Nilsson L, et al. RNAi delivery by exosome-mimetic nanovesicles - Implications for targeting c-Myc in cancer. Biomaterials. 2016;102:231–238.
   PubMed Web of Science ®Google Scholar
• Gujrati V, Kim S, Kim SH, et al. Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy. ACS Nano. 2014;8(2):1525–1537.
   PubMed Web of Science ®Google Scholar
• O’Loughlin AJ, Mager I, de Jong OG, et al. Functional delivery of lipid-conjugated siRNA by extracellular vesicles. Mol Ther. 2017;25(7):1580–1587.
   PubMed Web of Science ®Google Scholar
• de Jong OG, Kooijmans SAA, Murphy DE, et al. Drug delivery with extracellular vesicles: from imagination to innovation. Acc Chem Res. 2019;52(7):1761–1770.
   PubMed Web of Science ®Google Scholar
• Lee JK, Park SR, Jung BK, et al. Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. PLoS One. 2013;8(12):e84256.
   PubMed Web of Science ®Google Scholar
• Ohno S, Takanashi M, Sudo K, et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther. 2013;21(1):185–191.
   PubMed Web of Science ®Google Scholar
• Kosaka N, Iguchi H, Yoshioka Y, et al. Competitive interactions of cancer cells and normal cells via secretory microRNAs. J Biol Chem. 2012;287(2):1397–1405.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen X, Tian B, et al. Nucleolin-targeted extracellular vesicles as a versatile platform for biologics delivery to breast cancer. Theranostics. 2017;7(5):1360–1372.
   PubMed Web of Science ®Google Scholar
• Shiozawa K, Shuting J, Yoshioka Y, et al. Extracellular vesicle-encapsulated microRNA-761 enhances pazopanib resistance in synovial sarcoma. Biochem Biophys Res Commun. 2018;495(1):1322–1327.
   PubMed Web of Science ®Google Scholar
• Santos JC, Lima NDS, Sarian LO, et al. Exosome-mediated breast cancer chemoresistance via miR-155 transfer. Sci Rep. 2018;8(1):829.
   PubMedGoogle Scholar
• Liu Y, Zhao L, Li D, et al. Microvesicle-delivery miR-150 promotes tumorigenesis by up-regulating VEGF, and the neutralization of miR-150 attenuate tumor development. Protein Cell. 2013;4(12):932–941.
   PubMed Web of Science ®Google Scholar
• Naseri Z, Oskuee RK, Jaafari MR, et al. Exosome-mediated delivery of functionally active miRNA-142-3p inhibitor reduces tumorigenicity of breast cancer in vitro and in vivo. Int J Nanomedicine. 2018;13:7727–7747.
   PubMed Web of Science ®Google Scholar
• Heiser A, Coleman D, Dannull J, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest. 2002;109(3):409–417.
   PubMed Web of Science ®Google Scholar
• Lesterhuis WJ, De Vries IJ, Schreibelt G, et al. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Res. 2010;30(12):5091–5097.
   PubMed Web of Science ®Google Scholar
• Weide B, Pascolo S, Scheel B, et al. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother. 2009;32(5):498–507.
   PubMed Web of Science ®Google Scholar
• Fotin-Mleczek M, Duchardt KM, Lorenz C, et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother. 2011;34(1):1–15.
   PubMed Web of Science ®Google Scholar
• Wahlgren J, De LKT, Brisslert M, et al. Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res. 2012;40(17):e130.
   PubMed Web of Science ®Google Scholar
• Dannull J, Haley NR, Archer G, et al. Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. J Clin Invest. 2013;123(7):3135–3145.
   PubMed Web of Science ®Google Scholar
• Wagner MJ, Mitra R, McArthur MJ, et al. Preclinical mammalian safety studies of EPHARNA (DOPC nanoliposomal EphA2-targeted siRNA). Mol Cancer Ther. 2017;16(6):1114–1123.
   PubMed Web of Science ®Google Scholar
• Kim SM, Yang Y, Oh SJ, et al. Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting. J Control Release. 2017;266:8–16.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhou X, Wei M, et al. In vitro and in vivo RNA inhibition by CD9-HuR functionalized exosomes encapsulated with miRNA or CRISPR/dCas9. Nano Lett. 2019;19(1):19–28.
   PubMed Web of Science ®Google Scholar
• Kim D, Bae S, Park J, et al. Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nat Methods. 2015;12(3):237–243. 1 p following 43.
   PubMed Web of Science ®Google Scholar
• Mulvihill JJ, Capps B, Joly Y, et al. Ethical issues of CRISPR technology and gene editing through the lens of solidarity. Br Med Bull. 2017;122(1):17–29.
   PubMed Web of Science ®Google Scholar
• Yao C, Liu J, Wu X, et al. Reducible self-assembling cationic polypeptide-based micelles mediate co-delivery of doxorubicin and microRNA-34a for androgen-independent prostate cancer therapy. J Control Release. 2016;232:203–214.
   PubMed Web of Science ®Google Scholar
• Jayaram S, Gupta MK, Polisetty RV, et al. Towards developing biomarkers for glioblastoma multiforme: a proteomics view. Expert Rev Proteomics. 2014;11(5):621-639.
   PubMed Web of Science ®Google Scholar
• Qiao X, Yang Y, Huang R, et al. E-Jet 3D-printed scaffolds as sustained multi-drug delivery vehicles in breast cancer therapy. Pharm Res. 2019;36(12):182.
   PubMed Web of Science ®Google Scholar
• Sayour EJ, Grippin A, De Leon G, et al. Personalized tumor RNA loaded lipid-nanoparticles prime the systemic and intratumoral milieu for response to cancer immunotherapy. Nano Lett. 2018;18(10):6195–6206.
   PubMed Web of Science ®Google Scholar
• Suzuki HI, Spengler RM, Grigelioniene G, et al. Deconvolution of seed and RNA-binding protein crosstalk in RNAi-based functional genomics. Nat Genet. 2018;50(5):657–661.
   PubMed Web of Science ®Google Scholar
• Almeida MI, Nicoloso MS, Zeng L, et al. Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells. Gastroenterology. 2012;142(4):886–96.e9.
   PubMed Web of Science ®Google Scholar
• Jaiswal A, Peddinti G, Akimov Y, et al. Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells. Genome Med. 2017;9(1):51.
   PubMedGoogle Scholar
• Khalil IA, Yamada Y, Harashima H. Optimization of siRNA delivery to target sites: issues and future directions. Expert Opin Drug Deliv. 2018;15(11):1053–1065.
   PubMed Web of Science ®Google Scholar
• Kim OY, Park HT, Dinh NTH, et al. Bacterial outer membrane vesicles suppress tumor by interferon-gamma-mediated antitumor response. Nat Commun. 2017;8(1):626.
   PubMedGoogle Scholar
• Murillo OD, Thistlethwaite W, Rozowsky J, et al. exRNA atlas analysis reveals distinct extracellular RNA cargo types and their carriers present across human biofluids. Cell. 2019;177(2):463–77.e15.
   PubMed Web of Science ®Google Scholar
• McNeill B, Ostojic A, Rayner KJ, et al. Collagen biomaterial stimulates the production of extracellular vesicles containing microRNA-21 and enhances the proangiogenic function of CD34(+) cells. Faseb J. 2019;33(3):4166–4177.
   PubMed Web of Science ®Google Scholar
• Kumarswamy R, Volkmann I, Thum T. Regulation and function of miRNA-21 in health and disease. RNA Biol. 2011;8(5):706–713.
   PubMed Web of Science ®Google Scholar